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Abstract: Human hepatitis B virus (HBV) infection and HBV-related
diseases remain a major public health problem. Individuals coin-
fected with its satellite hepatitis D virus (HDV) have more severe dis-
ease. Cellular entry of both viruses is mediated by HBV envelope
proteins. The pre-S1 domain of the large envelope protein is a key
determinant for receptor(s) binding. However, the identity of the
receptor(s) is unknown. Here, by using near zero distance photo-
cross-linking and tandem afﬁnity puriﬁcation, we revealed that the
receptor-binding region of pre-S1 speciﬁcally interacts with sodium
taurocholate cotransporting polypeptide (NTCP), a multiple trans-
membrane transporter predominantly expressed in the liver. Silenc-
ing NTCP inhibited HBV and HDV infection, while exogenous NTCP
expression rendered nonsusceptible hepatocarcinoma cells suscepti-
ble to these viral infections. Moreover, replacing amino acids 157–
165 of nonfunctional monkey NTCP with the human counterpart
conferred its ability in supporting both viral infections. Our results
demonstrate that NTCP is a functional receptor for HBV and HDV.
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hepatitis B virus (HBV) is an unsolved global health challenge.
Current treatment strategies, based on interferon-alpha or nucle-
os(t)ide analogues have been shown to control viral infection and
reduce liver disease. However, available treatments are far from
satisfactory as they largely fail to eradicate HBV or hepatitis delta
virus (HDV) [1]. Although the HBV genome replicates in a variety
of cell lines, the virus can only infect primary human and Tupaia
hepatocytes (PHH and PTH) [2,3] and the bipotent differentiated
HepaRG liver progenitor cell line [4]. Despite tremendous pro-
gress in the molecular characterization of HBV replication and
assembly, the host determinants mediating the ﬁrst steps of
infection remain poorly deﬁned, limiting the development of
robust in vitro models supporting the complete HBV life cycle.
Although other hepadnaviruses (e.g., duck hepatitis B virus
[DHBV]) share some functional and structural properties with
HBV and are therefore used as models for HBV-host interactions,
functional data suggest that entry pathways of these viruses dif-
fer [5]. Indeed, the functional relevance of cellular receptors iden-
tiﬁed for DHBV (such as carboxypeptidase D) could not be
conﬁrmed for HBV (for review see [5]).
The pre-S1 domain of the HBV encoded large surface envelope
protein plays a role in particle entry. Indeed, a peptide derived
from the pre-S1 protein inhibits HBV infection of human hepato-
cytes [4,6,7] and chimeric uPA/SCID mice [8]. Since HDV utilizes
the envelope proteins of HBV, it is assumed to enter hepatocytes
via a similar mechanism [5]. There is accumulating evidence that
HBV attaches to cells via heparan sulfate proteoglycans [9–11].
Several cell surface proteins have been reported to interact with
HBV envelope proteins but none of them have been conﬁrmed to
be an essential entry factor [5].
A recent study by Wenhui Li’s laboratory at the National Insti-
tute of Biological Sciences in Beijing, China, identiﬁed a novel
HBV and HDV receptor candidate [12]. Based on the previous
mapping studies by Schulze et al. [13], Wenhui Li’s team estab-
lished a photo cross-linking assay using a series of synthetic
pre-S1 peptides as ‘‘bait’’ to identify interacting proteins
expressed in Tupaia hepatocytes to screen for putative HBV entry
factors. The cross-linked peptide-protein complexes were puri-
ﬁed and analyzed by mass spectrometry (MS). Comparing the
MS results of the captured proteins with a Tupaia protein
database obtained by deep-sequencing the Tupaia transcriptome,
enabled Yan and colleagues to identify sodium taurocholate
cotransporting polypeptide (NTCP, also known as SLC10A1) as a
hepatocyte surface molecule binding pre-S1. NTCP is a member13 vol. 58 j 1246–1248
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Fig. 1. Putative model of sodium taurocholate co-transporting polypeptide (NTCP) as a co-factor for hepatitis B and D virus entry. HBV or HDV ﬁrst attaches to
heparan sulfate (HS) [9–11]. The virus may then interact with NTCP through the pre-S1 domain of the large envelope protein as shown by Yan et al. [12]. NTCP is a
glycoprotein localizing to the basal membrane of hepatocytes. The key function of NTCP is the Na+-dependent uptake of bile acids allowing to maintain the enterohepatic
circulation of bile acids [14]. Residues 157–165 of NTCP have been suggested to be critical for pre-S1 binding [12]. Putative other unknown HBV/HDV receptors during viral
entry are indicated. The subsequent steps of HBV/HDV entry are largely unknown. Clathrin [20] and caveolin [21]-mediated pathways have been suggested but remain to be
conﬁrmed. After the import of the HBV genome into host cell nucleus, viral relaxed circular DNA is converted into covalently closed circular DNA (cccDNA), from which
genomic and subgenomic RNAs are transcribed.
JOURNAL OF HEPATOLOGYof the solute carrier family 10 (SLC10), the major bile acid uptake
system in human hepatocytes, that localizes to the basolateral
hepatocyte membrane (Fig. 1). NTCP is a 349-amino acid integral
membrane glycoprotein comprising 7 or 9 transmembrane (TM)
domains according to topology studies on a related SLC10 family
member, apical sodium-dependent bile acid transporter (ASBT)
[14–16]. The ability of NTCP to bind HBV pre-S1 was conﬁrmed
using NTCP transfected 293T cells. Silencing NTCP expression in
PTHs, HepaRG or PHHs partially reduced HBV or HDV infection.
NTCP expression in non-permissive HepG2 or HuH7 hepatoma
cells rendered these cells susceptible to low level HBV or HDV
infection, respectively. Finally, the authors combined phyloge-
netic analysis with mutagenesis studies to identify a putative role
for NTCP amino acids 157–165 in viral infection.
As shown for many other viruses, ‘‘cellular receptor proteins’’
can act in several ways to mediate viral entry, including viral
attachment, post-binding transport and viral fusion [17]. Hepatic
NTCP expression is regulated by a number of familiar pathways,
notably the glucocorticoid receptor, the retinoic acid receptor
and hepatic nuclear transcription factors HNF1a, HNF4a, and
HNF3b [18]. NTCP is a member of a family of 7 related solute car-
rier family transporters and has been shown to interact with a
variety of partner proteins. In addition to forming a homodimer,
NTCP can dimerise with other members of the SLC10A family,
notably SLC10A4 and SLC10A6 (sodium-dependent organic anion
transporter, SOAT). NTCP interaction with these partner proteins
regulate protein trafﬁcking in vitro and hints at possible mecha-
nisms for viral transport [19]. Resolving these outstanding issues
will clarify the role of NTCP in HBV internalization. Furthermore,
it will be of interest to explore NTCP or its regulatory factors as
antiviral targets.
The observations that silencing NTCP did not ablate HBV
infection of PHHs and that HepG2-NTCP cells support low levelJournal of Hepatology 2013HBV infection suggest that NTCP may not be the sole host factor
deﬁning liver permissivity to HBV, highlighting the need for addi-
tional studies in this area.
In summary, the work of Yan et al. provides an important
advance in our understanding of HBV entry and suggests new
avenues for the genesis of cell culture and animal model systems
that support HBV and HDV infection, enabling the development
of new antivirals and immunotherapies.Financial support
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